Although these studies are based on a small number of patients with cachexia, good tolerability and safety of ghrelin administered in such way has been demonstrated in patients with advanced disease (most with metastatic cancer) and with cancer cachexia in pancreatic, head and neck, lung, and gastrointestinal cancer. This evidence concerns the gene GHRL and Cachexia.